Pharmacokinetics and pharmacodynamics modeling of ritonavir boosted lonafarnib therapy in HDV patients: A phase 2 LOWR HDV-3 study

Dubey, Priya B.; Koh, Chang-Soon; Surana, Pallavi; Uprichard, Susan L.; Han, Ma Ai Thanda; Fryzek, Nancy; Subramanya, Gitanjali; Kapuria, Devika; Etzion, Ohad; Takyar, Varun; Rotman, Yaron; Yurdaydın, Cihan; Glenn, Jeffrey S.; Cotler, S.J.; Heller, Theo; Dahari, Harel

doi:10.1016/s0168-8278(18)31263-7

Search citation statements

Order By: Relevance

Paper Sections

Select...

Farnesyl Transferase Inhibitor Lonafarnib1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBsAg levels were assessed in both the LOWR HDV-1 and LOWR HDV-3 studies, conducted in Ankara and at the NIH, respectively; For treatment durations of up to 24 weeks, HBsAg levels were not affected with either high dose lonafarnib monotherapy or lonafarnib in combination with ritonavir. 55,57 Interestingly, extending treatment duration to 48 weeks did not appear to increase efficacy. For example, with all oral therapy, a >2log decline in HDV RNA was only observed in 2 out of 5 patients.…”

Section: Farnesyl Transferase Inhibitor Lonafarnibmentioning

confidence: 95%

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Yurdaydın

Abbas

Buti³

et al. 2019

Journal of Hepatology

View full text Add to dashboard Cite

Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible ''trial endpoints") that could be used across different clinical trials.

show abstract

Section: Farnesyl Transferase Inhibitor Lonafarnibmentioning

confidence: 95%